News
CRDF
5.34
-7.13%
-0.41
Weekly Report: what happened at CRDF last week (0318-0322)?
Weekly Report · 4d ago
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
NASDAQ · 03/21 11:55
Weekly Report: what happened at CRDF last week (0311-0315)?
Weekly Report · 03/18 11:50
Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going
NASDAQ · 03/14 12:50
Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last?
NASDAQ · 03/14 12:08
12 Health Care Stocks Moving In Wednesday's Intraday Session
Heron Therapeutics shares rose 35.4% to $3.19 during Wednesday's regular session. The company's, Q4 earnings came out yesterday. Trxade Health (NASDAQ:MEDS) shares fell 22.6% during the session. NuCana stock rose 34.32% and Cardiff Oncology shares increased by 27.9%.
Benzinga · 03/13 17:31
ETRN, CRDF and KC are among pre market gainers
On the Move ETRN, CRDF and KC are among pre market gainers. Kidpik (PIK) +281%. L.S. Starrett (SCX) Enters into a Merger Agreement with MiddleGround Capital to become a private company.
Seeking Alpha · 03/11 13:30
Weekly Report: what happened at CRDF last week (0304-0308)?
Weekly Report · 03/11 11:46
Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Seeking Alpha · 03/09 00:37
What Makes Cardiff Oncology (CRDF) a Strong Momentum Stock: Buy Now?
NASDAQ · 03/06 17:00
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
Cardiff Oncology, Inc. Is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Five abstracts will be presented in a poster session at the American Association for Cancer Research Annual Meeting in 2024 in San Diego.
Barchart · 03/06 15:05
Cardiff Oncology Price Target Raised to $14.00/Share From $12.00 by HC Wainwright & Co.
Dow Jones · 03/06 11:59
Cardiff Oncology Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/06 11:59
HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Raises Price Target to $14
Benzinga · 03/06 11:49
Crude Oil Down Over 1%; Quoin Pharmaceuticals Shares Spike Higher
U.S. Stocks traded lower toward the end of trading on Monday. The Dow traded down 0.20% to 39,007.30 while the NASDAQ fell 0.18%. Super Micro Computer, Inc. Will join the S&P 500 Index on March 18. Utilities shares rose by 0.9% on Monday while communication services shares fell by 1.6%. European shares closed mostly lower while Asian markets closed higher.
Benzinga · 03/04 19:34
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Bitdeer Technologies Group shares jumped 10.2% to $7.45 on Monday. The company announced successful testing of its SEAL01 Bitcoin mining chip. BitFuFu Inc. Shares jumped 107% in the mid-day session. Macy's, Inc. And MGE also rose amid strength in the price of Bitcoin.
Benzinga · 03/04 18:29
MINM, RMCO and GRFS among pre-market losers
On the Move MINM, RMCO and GRFS among pre-market losers. BioVie (BIVI) -46% on prices $21M equity offering. Astra Space (ASTR) and Minim (MINM) among the day's losers.
Seeking Alpha · 03/04 13:17
Weekly Report: what happened at CRDF last week (0226-0301)?
Weekly Report · 03/04 11:49
Health Care Sector Update for 03/01/2024: CRDF, BIVI, STTK, CVS, WBA
NASDAQ · 03/01 20:54
Crude Oil Rises Over 2%; Fisker Shares Plummet
U.S. Stocks traded higher toward the end of trading on Friday. The Dow traded up 0.23% while the Nasdaq Composite gained more than 1%. Energy shares rose by 1.4% on Friday; utilities shares fell 1.3%. Asian markets closed higher on Friday, with European and Asian markets also higher.
Benzinga · 03/01 19:32
More
Webull provides a variety of real-time CRDF stock news. You can receive the latest news about Cardiff Oncology Inc through multiple platforms. This information may help you make smarter investment decisions.
About CRDF
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies across a range of cancers with unmet medical needs. The Company is focused on tumor vulnerabilities with treatment combinations of onvansertib, its selective PLK1 inhibitor, and standard of care (SoC) therapeutics. The Company has five ongoing clinical trials of onvansertib, including two trials (TROV-054 and ONSEMBLE) in second-line treatment in patients with KRAS-mutated Metastatic Colorectal Cancer (mCRC), one trial in second-line treatment in patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC), and two investigator-initiated trials in patients with unresectable locally advanced or metastatic Triple Negative Breast Cancer (TNBC) and relapsed Small Cell Lung Cancer (SCLC). The Company has third-party manufacturers and distributors to supply and distribute onvansertib used in its clinical studies and nonclinical development programs.